This occurs mainly in patients with large tumor burden, high lactate dehydrogenase levels, uveal melanoma, mucosal melanoma, brain metastases and melanoma unresponsive to anti-PD-1 therapies. This evidence concerns the gene PDCD1 and neoplasm.